AVANOS MEDICAL, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $701.2M | $687.8M | $673.3M | $684.1M | $587.0M |
| Gross profit | $353.9M | $381.3M | $379.7M | $394.2M | $299.2M |
| Operating income | -$61.6M | -$396.2M | $4.2M | $35.5M | -$39.0M |
| Cost of revenue | $347.3M | $306.5M | $293.6M | $289.9M | $287.8M |
| Cash from operations | $74.7M | $100.7M | $32.4M | $90.9M | $87.3M |
| Capital expenditure | $31.6M | $17.8M | $17.8M | $19.3M | $21.0M |
| Free cash flow | $43.1M | $82.9M | $14.6M | $71.6M | $66.3M |
| Share repurchases | $3.3M | $12.8M | $19.1M | $45.5M | $11.5M |
| Impairments | $77.0M | $336.5M | $0 | — | $7.9M |
| Total assets | $1.1B | $1.2B | $1.7B | $1.8B | $1.6B |
| Total liabilities | $295.5M | $325.7M | $456.1M | $495.7M | $333.0M |
| Total debt | $100.8M | $135.2M | $168.8M | $233.4M | $130.0M |
Shares outstanding 46.8M · Free float 96.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.